Remdesivir Can Shorten Coronavirus Recovery Time by About 4 Days

Henrietta Brewer
May 30, 2020

The Searle Company Limited has successfully entered into an exclusive licensing and marketing agreement with Beximco Pharmaceuticals, Bangladesh for marketing of Covid-19 drug Remdesivir, informed the company in a statement to the Pakistan Stock Exchange on Friday. But Marty said that it provides additional data backing up a separate study by the National Institute of Allergy and Infectious Diseases, which in preliminary results found that patients who received remdesivir spent four fewer days in the hospital than those who didn't get the medication. Roche is committed to sharing data from the COVACTA study as soon as possible this summer.

USA pharma giant Gilead Sciences has applied to India's drug regulator seeking marketing authorisation for its anti-viral drug remdesivir, which is being touted as a potential treatment for COVID-19.

Roche is also nearly done with enrollment of another Phase III trial, COVACTA, studying intravenous Actemra/RoActemra alone with standard of care (SOC) compared to placebo plus SOC in hospitalized adults with severe COVID-19 pneumonia.

Hershey Medical Center is one of approximately 100 hospitals internationally participating in the continuation of the study and is the only hospital in central Pennsylvania to participate in the clinical trial.

Its Commission on Human Medicines and the Expert Working Group on COVID-19 gave the scientific opinion after a rigorous evaluation of the benefit/risk balance of the medicine based on the data available.

The U.S. Food and Drug Administration has issued an emergency use authorization of remdesivir, meaning physicians can prescribe the drug to patients outside clinical trials if they feel it will benefit their patients. It will also continue to be used in clinical trials.

They said the patients were randomly assigned to receive local standard care and a 10-day course of the antiviral remdesivir intravenously, or local standard care and a placebo.

For more information on how Genentech is responding to the global COVID-19 pandemic, please visit our COVID-19 response page. Key secondary endpoints include mortality, mechanical ventilation, clinical status at day 14, time to clinical improvement, and time to discharge. Individuals with mild or no apparent symptoms will not be included in the study. It is also used to treat polyarticular juvenile idiopathic arthritis, giant cell arteritis and for chimeric antigen receptor CAR-T-cell-induced severe or life-threatening cytokine release syndrome (CRS). Actemra is approved in the European Union, where it is known as RoActemra, and several other countries, including China, India, Brazil, Switzerland and Australia.

Other reports by iNewsToday